Status:
COMPLETED
Regulation of Lipoprotein Transport in Metabolic Syndrome
Lead Sponsor:
The University of Western Australia
Collaborating Sponsors:
National Heart Foundation, Australia
Conditions:
Obesity
Lipid Disorders
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.
Detailed Description
The metabolic syndrome (MetS) portends diabetes and cardiovascular disease (CVD). Dyslipoproteinaemia, reflected by elevated plasma triglyceride and reduced high-density lipoprotein (HDL) concentratio...
Eligibility Criteria
Inclusion
- Any three of the following:
- Waist circumference \> 102 cm
- Triglycerides \> 150 mg/dL
- HDL-cholesterol \< 40 mg/dL
- Blood glucose \> 110 mhg/dL
- Blood pressures \> 130/85 mmHg
Exclusion
- Triglycerides \> 500 mg/dL
- Diabetes mellitus
- CVD
- Consumption of \> 30 g alcohol/day
- Use of agents affecting lipid metabolism
- APOE2/E2 genotype
- Creatinemia (\> 120 umol/L)
- Hypothyroidism
- Abnormal liver and muscle enzymes
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00841217
Start Date
April 1 2003
End Date
December 1 2008
Last Update
February 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Western Australia
Perth, Western Australia, Australia, 6000